Search Results

First Wave BioPharma, Inc. announced it has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease.

First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”) today announced that the company has signed a non-binding term sheet for a business combination with ImmunogenX, a clinical-stage biotherapeutics company developing Phase 3-ready latiglutenase, a potentially first-in-class, targeted, oral biotherapeutic for celiac disease.

ImmunogenX is pleased to report the successful completion of the CeliacShield™ trial ( NCT03585478 ), focused on treating celiac disease (CeD) patients.

ImmunogenX is happy to announce the successful completion of the CeliacShield™ trial (NCT03585478). This gluten-challenge trial measured several outcomes including histology, symptoms, serology, and gluten in urine

The NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has awarded a grant to ImmunogenX to conduct a Phase 2 clinical trial using latiglutenase, an investigational drug for celiac disease (CD)

The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has awarded a grant to ImmunogenX to conduct a Phase 2 trial for latiglutenase, an investigational drug for celiac disease (CD).

Entero Therapeutics, Inc. today unveiled its new corporate name and website.